The public record of what the powerful say about the futureAll times UTCYour time ATHENA News Room is liveSealed daily · anchored in BitcoinΕλληνικά A Tekmerion product
THE ORACLE HUNTERS • EVERY PROPHECY ON THE RECORD •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The Oracle HuntersEvery prophecy, on the record. · Οἱ Κυνηγοὶ τῶν ΧρησμῶνUnder development

← Tracking the Prophets

AstraZeneca

Institution - official statements with no named speaker · GBR

Track record: No forecast checked yet (14 not due, 52 being checked).
68forecasts & commitments on the record
29%can be checked as stated
38average ambiguity (0-100)
0goalpost moves recorded
0confirmed U-turns

Timeline

20162016: Due - being checked2016: Not due yet2016: Due - being checked2016: Due - being checked2016: Due - being checked2016: Too vague to check2016: Too vague to check2016: Not due yet (+15 more)20172017: Due - being checked2017: Due - being checked2017: Due - being checked2017: Due - being checked20182018: Due - being checked2018: Due - being checked2018: Due - being checked2018: Due - being checked2018: Due - being checked2018: Due - being checked2018: Due - being checked20192019: Due - being checked2019: Due - being checked2019: Due - being checked20202020: Due - being checked2020: Due - being checked2020: Due - being checked2020: Due - being checked2020: Due - being checked2020: Due - being checked2020: Due - being checked2020: Due - being checked20212021: Due - being checked2021: Not due yet2021: Due - being checked2021: Due - being checked2021: Due - being checked20222022: Due - being checked2022: Not due yet2022: Due - being checked20232023: Due - being checked2023: Due - being checked2023: Not due yet2023: Due - being checked2023: Due - being checked2023: Not due yet2023: Due - being checked20242024: Due - being checked2024: Due - being checked2024: Not due yet2024: Not due yet2024: Not due yet202520262026: Not due yet2026: Not due yet2026: Not due yet
came true partly did not not due / being checked / too vague

Calibration score: shown after 10 checked forecasts with a stated likelihood (now 0).
How they speak about the future: based on data 64, stated on authority 3, educated guess 1.
Kinds of claim: forecast 63, mixed claim 2, speculation 2, commitment 1. · Download this report card as a picture

In the nine words

πρόγνωσιςInference from evidence62 · 91%μαντείαInspired knowledge3 · 4%εἰκασίαConjecture2 · 3%χρησμοδοσίαInstitutional delivery1 · 1%
How to read this Each box is one sentence a public figure or institution said about the future, word for word, with a link to the official text. Can be checked means it names what will happen, by when, and how likely - so it can be compared with official figures later. Too vague to check means it does not. Ambiguity (0-100) is how many different ways the sentence can be read. When the date passes, the forecast is compared with official data and marked came true, partly or did not come true. Labels judge the sentence, never the person. Full guide and glossary.

On the record (68)

Core Tax rate is expected to be between 18-22%
of patients with CKD will be diagnosed by 2030, with associated
The Core Tax rate is expected to be between 18-22%
of plaintiffs is currently scheduled for May 2025.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 56/100implied call / likelihood: No · 40% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
dividend for FY 2024 will increase by $0.20 per share to $3.10 per
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2024Due - being checked
Launch of 20 new medicines expected by 2030
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2030Not due yet
Company will be carbon zero for Scope 1 and 2 emissions and by 2030
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2030Not due yetclimate
sustained growth beyond 2030, the Company will continue investing
China has been submitted, with a decision expected in H2 2024.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2024Due - being checked
maintain over 50 million trees worldwide by end of 2025, in
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 56/100below the RIM-1 standarddue 31 Dec 2025Due - being checked
The Core Tax Rate is expected to be between 18-22%
dividend for 2023, payable on 11 September 2023, will be 11 August
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2023Due - being checked
approximately $1.9bn by the end of 2025.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 56/100below the RIM-1 standarddue 31 Dec 2025Due - being checked
expected to be substantially complete by the end of 2030, realising
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2030Not due yet
are expected to be substantially complete by the end of 2025, with
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
announced that by the end of 2025, 95% of its key suppliers will
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2025Due - being checked
of new long-term debt, issued in May and June 2021, $4bn of term
dividend for 2022, payable on 12 September 2022, will be 12 August
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2022Due - being checked
attend a youth leadership summit in Tokyo in May 2022.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 56/100implied call / likelihood: No · 40% · probablebelow the RIM-1 standarddue 31 Dec 2022Due - being checked
Health Organization (WHO), with c.80% of the doses going to low and
Tax will increase from 19% to 25% from 1 April 2023.
πρόγνωσις · Inference from evidenceCan be checkedForecastbased on dataambiguity 0/100implied call / likelihood: Yes · 85% · for the most partmeets the RIM-1 standarddue 31 Dec 2023Due - being checkedfiscal
Results from the NAVIGATOR trial will be presented at this year's
μαντεία · Inspired knowledgePartly checkableForecaststated on authorityambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2021Due - being checked
dividend for 2021, payable on 13 September 2021, will be 13 August
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2021Due - being checked
will cease when the swap matures in 2021.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2021Due - being checked
From 2021, AstraZeneca is likely to recognise
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2021Due - being checked
regulatory decision expected at the end of this year.
μαντεία · Inspired knowledgePartly checkableForecaststated on authorityambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2020Due - being checked
entity that, once fully operational in 2021, will mean that
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2021Due - being checked
business of IBOR reform will be assessed this year.
μαντεία · Inspired knowledgePartly checkableForecaststated on authorityambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2020Due - being checked
such the data readout is now expected in 2021.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2021Due - being checked
patent no. 2568391 (expiry May 2025) related
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 56/100implied call / likelihood: No · 40% · probablebelow the RIM-1 standarddue 31 Dec 2025Due - being checked
dividend for 2020, payable on 14 September 2020, will be 14 August
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2020Due - being checked
2020, with an overall full completion of the building expected in
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2020Due - being checked
strategy up to 2025 and future reporting for 2019 onwards will
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2025Due - being checked
is expected that by 2022, the Companies entire US fleet will be
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2022Due - being checked
is expected that by 2022 our entire US fleet will be made up of
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2022Due - being checked
AstraZeneca expects the generic Crestor impact to recede significantly from 2019.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2019Due - being checked
decision expected in the second half of 2019.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2019Due - being checked
medicines are expected to be launched between 2014 and 2020, of
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2020Due - being checked
transaction is expected to close by the end of Q2 2018, subject to
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 30 Jun 2018Due - being checked
will leave the EU on 29 March 2019 and relevant EU law and
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2019Due - being checked
trial results in 2019 that will further characterise the role of
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2019Due - being checked
will make regulatory submissions for Bevespi Aerosphere in Japan and China in 2018,
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2018Due - being checked
the original agreement will be made to AstraZeneca in 2018, if the
πρόγνωσις · Inference from evidencePartly checkableMixed claimbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2018Due - being checked
expected to be submitted for US regulatory review in 2018.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2018Due - being checked
comparisons expected to ease in the second half of FY 2017, when
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2017Due - being checked
for 2016, payable on 20 March 2017, will be 17 February 2017.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2017Due - being checked
Diabetes growth of 6% in the third quarter, reflecting an expected
Stockholm will trade ex-dividend from 10 August 2017.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2017Due - being checkedtrade
The Company continues to anticipate EU approval in the first half of 2017.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 36/100implied call / likelihood: Yes · 70% · probablebelow the RIM-1 standarddue 31 Dec 2017Due - being checked
A further payment of $1.5bn will be paid either on receipt of the first regulatory approval for acalabrutinib for any indication in the US, or the end of 2018, depending on which is first.
πρόγνωσις · Inference from evidencePartly checkableForecastbased on dataambiguity 56/100implied call / likelihood: Yes · 85% · for the most partbelow the RIM-1 standarddue 31 Dec 2018Due - being checked

Showing the newest 50 - the ledger has all 68.